<DOC>
	<DOCNO>NCT00000393</DOCNO>
	<brief_summary>To study safety , toxicology , activity Peptide T ( D-Ala-1-peptide-T-amide ) humans find ability peptide T prevent , halt , and/or reverse AIDS-associated immunologic disturbance . Recent information suggest central nervous system ( CNS ) often impaired HIV-infected individual . The dysfunction CNS may either direct indirect result HIV infection . One method prevent HIV infection block entry virus cell body . Peptide T show laboratory evidence block entrance HIV cell susceptible HIV infection . Studies do indicate peptide T nontoxic dos use study . AIDS patient minimal ( group 1 ) moderate ( group 2 ) cognitive dysfunction ( mental impairment ) receive increase schedule three dosage level peptide T. All patient receive intravenous ( IV ) dose peptide T 10 day follow intermediate dose high dose , intravenously 10 day . Following successful completion 3 IV dos , four patient participate intranasal pharmacokinetic ( blood level study ) dosage trial 3 dos ( different IV ) peptide T 3 successive day . Follow-up continue 1 year .</brief_summary>
	<brief_title>A Phase I Trial Peptide T : Efficacy Neuropsychiatric Complications Acquired Immunodeficiency Syndrome ( AIDS ) .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>History either opportunistic infection and/or Kaposi 's sarcoma , and/or serologic evidence past infection HIV . Ability give inform consent . Allowed discourage : Antiretroviral medication . Immunomodulating medication . Psychoactive medication . Not breastfeed Abstinence agree use barrier method birth control / contraception study Not pregnant Negative pregnancy test CD4 &gt; = 200 cells/mm3 ( 200 300 400 500 600 700 800 plus ) . Creatinine &lt; = 1.6 mg/dl Hemoglobin &gt; = 12 g/dl Platelet Count &gt; = 100000 /mm3 Patients follow disease symptom exclude : Spaceoccupying lesion brain . Lifethreatening opportunistic infection time entry trial . History major psychiatric illness prior 1977 time initial exposure HIV , know . Patients follow disease symptom exclude : Spaceoccupying lesion brain . Lifethreatening opportunistic infection time entry trial . History major psychiatric illness prior 1977 time initial exposure HIV , know . Excluded within 4 week study entry : Antiretroviral agent . Anticancer treatment . Psychoactive agent . Excluded within 4 month study entry : Suramin . Avoid : Antiretroviral medication . Immunomodulating medication . Psychoactive medication . Excluded within 4 week study entry : Radiation . Breastfeeding Positive pregnancy test Pregnant No abstinence agreement use barrier method birth control / contraception study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>